Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

Trial Profile

Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Dapagliflozin/metformin (Primary) ; Dapagliflozin; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Dec 2015 Results published in the Clinical Therapeutics
    • 29 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top